Clinical Trial Update: Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating lenalidomide in patients with progressive or recurrent multiple myeloma after an allogeneic stem cell transplant; results have…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2017-04-18